{"groups":[{"description":"Cyclophosphamide + Bortezomib + Dexamethasone for three 21-day cycles","id":"FG000","title":"Cyclophosphamide + Bortezomib + Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Pregression of other disease"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"395"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"353"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Out of 401 participants, 399 participants were treated in both the Parts. Out of 399 participants, 395 participants were evaluated as 4 participants who had received cyclophophamide dose of greater than 1350 mg/m\\^2 per cycle in Part 1 were excluded.","recruitmentDetails":"401 participants were enrolled at 41 study sites in Germany."}